If you have enough clout to bring a US$230B giant like Takeda to the negotiating table to do a licensing deal for 1 product involving mesenchymal lineage then the chances of attracting $$ to the rest of the MSB portfolio are pretty good.
Keeping in mind Takeda did a huge deal €355 million and double digit royalties with Tigenix for Cx601
https://www.takeda.com/newsroom/new...nal-fistulas-in-patients-with-crohns-disease/
Whats MSB's portfolio worth if we start seeing deals?
JCR and MEDIPAL JV in the US, page-3
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.140(10.4%) |
Mkt cap ! $1.701B | |||
| Open | High | Low | Value | Volume |
| $1.37 | $1.54 | $1.37 | $23.10M | 15.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 24758 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 73626 | 3 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |